An ongoing dialogue on HIV/AIDS, infectious diseases,
February 17th, 2013
An Adherence Intervention That Works — But There’s a Catch
In a previous post, we reviewed the various flavors of medication non-adherence, and concluded with this tantalizing line:
Next up: An Adherence Intervention that Actually Works — But There’s a Catch
Well here it is, just published online in JAMA Internal Medicine.
Dr. Robert Gross (a long-time HIV adherence researcher from U Penn) and colleagues enrolled 180 patients with HIV RNA of 1000 or higher who were starting or changing their HIV regimen. They were randomized to usual care versus an adherence intervention called Managed Problem Solving, or “MAPS”. The study took place in three outpatient clinics in Philadelphia; study subjects could be treatment-naive or treatment-experienced. Participants were predominantly black, and 60% were men.
So what constituted MAPS? A trained “interventionist” — someone who went through 15 hours of study-specific education — met with the patient for 4 in-person sessions, some as long as 90 minutes; this was supplemented with 12 subsequent phone calls and then additional monthly calls for a year.
The good news is that the intervention worked: Those in the MAPS group had a 1.78 (95% CI, 1.07-2.96) times greater chance of being in a higher adherence category than those receiving usual care, and there was a strong trend toward a higher likelihood of virologic suppression as well. Of note, 36% of the MAPS group and 26% of those in usual care dropped out of the study, a rate substantially higher than in most clinical trials of antiretroviral therapy, strongly suggesting this was a difficult-to-treat patient population.
So what’s the catch? To say that the MAPS intervention would be difficult to institute in a non-study setting is a colossal understatement, as the vast majority of HIV clinics could never deploy the training, the personnel, or the time for this kind of extra care. While the study authors argue that this intervention would nonetheless meet criteria for cost-effectiveness, such analyses typically take a societal perspective, and would not make MAPS feasible in a clinic with a limited budget.
The solution? Editorialists argue for “real time” adherence monitoring using electronic pill containers connected to a central server through mobile networks. When in place, clinicians could detect individual lapses in pill-taking behavior, and intervene only for people who need it. (Presumably they could also use portable jet-packs to go visit those who need a house call.)
I do think this paper shows some progress in addressing the tricky problem of non-adherent patients (at least those who show up for care). It also demonstrates just how hard it will be to improve adherence, at least until we have some way of identifying ahead of time — or in real-time, as suggested by the editorial — people who are bad at taking their meds.
Until then, enjoy this nifty 2-minute video on the HIV cascade from the CDC — your taxpayer dollars at work!
Categories: Health Care, HIV, Medical Education, Patient Care, Research
Tags: adherence, antiretroviral therapy, HIV
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “An Adherence Intervention That Works — But There’s a Catch”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing
- Sometimes You Just Need to Get Input from a Real Human Being
- Some Ruminations on CROI — Still the Best HIV Meeting
- Mystifying Abbreviations — Infectious Diseases Edition
- SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- The Eyes Have It March 5, 2026A 47-year-old man was brought to the ED by EMS after being found dyspneic in his car. He reported having been drinking for 6 hours before presentation. He noted a sensation of tongue swelling and difficulty breathing.
- Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges February 26, 2026In persons with HIV and barriers to adhering to antiretroviral therapy, a long-acting injectable treatment (monthly cabotegravir plus rilpivirine) resulted in better virologic control than standard oral ART.
- Microbial Flora in War Wounds from the Ukrainian Front Line February 26, 2026Battlefield injuries are often contaminated with potentially infecting microbes. In this study, swabs obtained in the field after injury were profiled. Microbes and potential antimicrobial-resistance genes were characterized.
- Primary Measles Infection February 26, 2026A previously healthy man presented with a 5-day history of fever, nausea, and vomiting and a 2-day history of an itchy rash. Examination showed an exanthem consisting of minute macules and subtly elevated papules.
- From Efficacy to Access in Long-Acting HIV Therapy February 26, 2026Over the past three decades, advances in antiretroviral therapy (ART) have dramatically improved life expectancy, decreased frailty, and improved quality of life for persons with human immunodeficiency virus (HIV).1,2 These gains have accrued primarily among those who can reliably access health care and adhere to daily treatment. For...
- The Eyes Have It March 5, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Inerventionist, health coach, case manager, health promotor, DOT specialist, maybe we just haven’t hit on the right title!